Key facts
- Enveric Biosciences has started IND-enabling genotoxicity studies for EB-003.
- EB-003 is Enveric's lead neuroplastogen candidate.
- Genotoxicity studies are required for Investigational New Drug (IND) applications.
Enveric Biosciences has officially begun the Investigational New Drug (IND)-enabling genotoxicity studies for its primary neuroplastogen candidate, known as EB-003. This marks a significant step in the drug development process, as these studies are a prerequisite for submitting an IND application to regulatory authorities, paving the way for potential human clinical trials.